James, a 42-year-old man previously diagnosed with relapsing-remitting multiple sclerosis (RRMS), has noticed a decline in his gait and worsening balance despite a lack of relapses. Review his case study from 2019 below to make your own assessment as to whether he may have transitioned to SPMS with active disease and decide on the best course of action for his care.
Throughout James’ case study you will find multiple choice questions. These do not have correct answers but are designed to support your clinical assessment of James’ case and to simulate a real-life clinical decision-making situation with a patient.
Beneath the case study you can watch a video of MS expert Dr Emma Tallantyre, clinical senior lecturer at Cardiff University, discussing the key characteristics of the case. Dr Tallantyre also explains how she would manage the case in the clinic and provides her assessment for James.
Watch Dr Tallantyre’s assessment of James’ case
*Indication: Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
- MAYZENT (siponimod) Summary of Product Characteristics.